Ferric Compound

CHICAGO — Ferric carboxymaltose, an IV iron replacement therapy, did not reduce the time to first HF hospitalization or CV death for patients with HF and iron deficiency, according to results of a late-breaking clinical trial.

In adults with HF with reduced ejection fraction and iron deficiency, ferric carboxymaltose modestly improved the endpoint of death, HF hospitalization and 6-minute walk distance but did not achieve the prespecified significance level.

The FDA approved ferric derisomaltose injection for the treatment of iron deficiency anemia in adults who had an intolerance or unsatisfactory response to oral iron or who have nonhemodialysis-dependent chronic kidney disease, according to a press release from the drug’s manufacturer.